[1] SOLDATOS G,COOPER M E.Diabetic nephropathy:important pathophysiologic mechanisms[J].Diabetes Res Clin Pract,2008,82(1):S75-9.
[2] WINGREN C,BORREBAECK C A.Antibody-based microarrays[J].Methods Mol Biol,2009,509:57-84.
[3] 郭啸华,刘志红,李恒,等.高糖高脂饮食诱导的2型糖尿病大鼠模型及其肾病特点[J].中国糖尿病杂志,2002,10(5):290-294.
[4] SRINIVASAN K,VISWANAD B,ASRAT L,et al.Combination of high-fat diet-fed and low dose streptozotocin-treated rat:a model for type 2 diabetes and pharmacological screening[J].Pharmacol Res,2005,52(4):313-320.
[5] 杨莉亚,刘必成.糖尿病肾病诊断生物标志物研究新进展[J].东南大学学报:医学版,2010,29(4):469-472.
[6] RIVERO A,MORA C,MUROS M,et al.Pathogenic perspectives for the role of inflammation in diabetic nephropathy[J].Clin Sci(Lond),2009,116(6):479-492.
[7] THONGBOONKERD V,SONGTAWEE N,SRITIPPAYAWAN S.Urinary proteome profiling using microfluidic technology on a chip[J].J Proteome Res,2007,6(5):2011-2018.
[8] LV L L,LIU B C.High-throughput antibody microarrays for quantitative proteomic analysis[J].Expert Rev Proteomics,2007,4(4):505-513.
[9] 戴厚永,汤日宁,刘必成,等.应用自发性高血压大鼠建立2型糖尿病早期肾损害模型[J].中华肾脏病杂志,2010,26(1):48-52.
[10] KIKUCHI Y,IKEE R,HEMMI N,et al.Fractalkine and its receptor,CX3CR1,upregulation in streptozotocin-induced diabetic kidneys[J].Nephron Exp Nephrol,2004,97(1):e17-25.
[11] LV L L,LIU B C.Clinical application of antibody microarray in chronic kidney disease:How far to go?[J].Proteomics Clin Appl,2008,2(7-8):989-996. |